Expert Interview
A Third View: Digging into Gilead's twice-yearly Lenacapavir 100 percent efficacy compared to daily Truvada for HIV
Ticker(s): GILDInstituition: University of Maryland
- Associate Professor of Medicine at the University of Maryland School of Medicine and Institute of Human Virology (IHV).
- Medical Director for the IHV's Center for International Health, Education, and Biosecurity (Ciheb).
- worked extensively in Rwanda since 2008 but has also served in other countries including Kenya, Malawi, and Zambia. His research in the US focuses on HIV-related cancers, and he runs the Infectious Diseases fellowship training program at the University of Maryland.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
